TOP TEN perturbations for 3497 (Homo sapiens)

Organism: Homo sapiens
Gene: 3497
Selected probe(set): 217469_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 3497 (217469_at) across 5339 perturbations tested by GENEVESTIGATOR:

IL-4; antiCD40 study 1 / normal resting B-cell sample

Relative Expression (log2-ratio):2.0985222
Number of Samples:2 / 2
Experimental IL-4; antiCD40 study 1
B-cells antiCD40/IL-4 activated for 30h.
Control normal resting B-cell sample
B cells resting for 30h.

APECED study 1 (candida positive) / C. albicans study 3

Relative Expression (log2-ratio):1.8411026
Number of Samples:2 / 3
Experimental APECED study 1 (candida positive)
Monocyte-derived dendritic cell samples (moDC`s) obtained after differentiation of peripheral blood mononuclear cells from female patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Monocyte-derived dendritic cells were stimulated with living Candida albicans (Moi=1) at a concentration of 100ng/ml for 24 hours before taking samples.
Control C. albicans study 3
Monocyte-derived dendritic cell samples (moDC`s) obtained after differentiation of peripheral blood mononuclear cells from female healthy volunteers. Monocyte-derived dendritic cells were stimulated with living Candida albicans (Moi=1) at a concentration of 100ng/ml for 24 hours.

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-1.4065466
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

DLBCL study 1 (germinal center B-cell like; unclassified) / DLBCL study 1 (activated B-cell like; unclassified)

Relative Expression (log2-ratio):1.3060589
Number of Samples:2 / 11
Experimental DLBCL study 1 (germinal center B-cell like; unclassified)
Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (germinal center B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; unclassified)
Unclassified B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

APECED study 1 (candida negative) / normal monocyte-derived dendritic cell sample

Relative Expression (log2-ratio):1.1671
Number of Samples:2 / 3
Experimental APECED study 1 (candida negative)
Monocyte-derived dendritic cell samples (moDC`s) obtained after differentiation of peripheral blood mononuclear cells from female patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Monocyte-derived dendritic cells were grown for 24 hours before taking samples.
Control normal monocyte-derived dendritic cell sample
Monocyte-derived dendritic cell samples (moDC`s) obtained after differentiation of peripheral blood mononuclear cells from female healthy volunteers.

human AB serum study 1 (late) / IL-4; GM-CSF study 1 (late)

Relative Expression (log2-ratio):1.078496
Number of Samples:3 / 6
Experimental human AB serum study 1 (late)
Monocytes, cultured in RPMI medium containing 10% human AB serum (HS) instead of FBS, and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.

brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-1.02211
Number of Samples:3 / 3
Experimental brefeldin A study 1 (0.5ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

B-CLL study 9 (CD19+; CD5+; untreated) / untreated normal B-cell sample (CD19+)

Relative Expression (log2-ratio):-0.99178886
Number of Samples:3 / 2
Experimental B-CLL study 9 (CD19+; CD5+; untreated)
Untreated CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control untreated normal B-cell sample (CD19+)
Untreated CD19+ B-cell samples from normal control subjects and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells.

multiple myeloma study 3 (primary) / MGUS study 1

Relative Expression (log2-ratio):-0.9860287
Number of Samples:5 / 3
Experimental multiple myeloma study 3 (primary)
Plasma cell (PC) samples from patients with primary multiple myeloma (MM).
Control MGUS study 1
Plasma cell (PC) samples from patients with monoclonal gammopathy of undetermined significance (MGUS).

tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):-0.97673035
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.